Business Wire

Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program

Share

Boehringer Ingelheim today announced the execution of the agreement on the acquisition of Labor Dr. Merk & Kollegen. The acquisition will enable Boehringer Ingelheim to further expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP) platform and cancer vaccines platforms. Labor Dr. Merk & Kollegen has outstanding experience in process development, manufacturing and analytical characterization in virology besides expertise in microbiology and cell culture. Labor Dr. Merk & Kollegen has already worked in close collaboration with Boehringer Ingelheim on viral-based therapy development since 2015.

“The acquisition of Labor Dr. Merk & Kollegen is strengthening our promising pipeline with diverse potential first-in-class cancer immunology and cancer cell directed therapies for patients with hard-to-treat cancer,” said Dr. Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit. “The trusting and highly effective collaboration between our scientists and the Labor Dr. Merk & Kollegen team has already contributed significantly to our progress in viral-based cancer therapies. We will welcome the Labor Dr. Merk & Kollegen team and look forward to jointly advancing our program in this area.”

Boehringer Ingelheim is taking cancer on by strengthening its position in cancer immunology, with a focus on cancer vaccines, oncolytic viruses, T-cell engagers, stromal modulators and myeloid cell modulators by combining its world-class, in-house research and development with that of highly innovative external companies. The addition of Labor Dr. Merk & Kollegen’s site will enable Boehringer Ingelheim to further strengthen its oncolytic virus and cancer vaccine development capabilities and capacities by establishing an end-to-end fully integrated center of excellence for virus development and clinical manufacturing. It will add to a series of strategic acquisitions and collaborations over the past years, including the acquisition of ViraTherapeutics and AMAL Therapeutics, which are contributing assets that will be further developed at Labor Dr. Merk & Kollegen’s site.

Labor Dr. Merk & Kollegen is a privately-held company founded in 1971. It is headquartered in Ochsenhausen, Germany, close to Boehringer Ingelheim’s Biberach R&D site. As a center of excellence in virology, Labor Dr. Merk & Kollegen has a long track record in GLP and GMP certified biosafety testing. In recent years Labor Dr. Merk & Kollegen established its GMP-virus manufacturing facility. With around 130 highly qualified and specialized employees, the company has built considerable expertise in process development, manufacturing and analytical characterization of viral therapeutics and oncolytic viral therapeutics. Labor Dr. Merk & Kollegen will be integrated with all employees as a new unit into Boehringer Ingelheim’s Development organization and continue to operate at its Ochsenhausen site. A future expansion is planned.

“Following our successful strategic partnership, we are really excited to join forces with Boehringer Ingelheim,” said Dr. Ingrid Rapp, CEO at Labor Dr. Merk & Kollegen. “Boehringer Ingelheim is a truly global pharmaceutical company with excellent R&D capacities. We look forward to taking our next development step in oncology as part of this outstanding team.”

The companies did not disclose the financial terms of the deal. The transaction is subject to the approval of the competition authorities in Germany. Closing will follow thereafter.

Please click on the following link for ‘Notes to Editors’:

http://www.boehringer-ingelheim.com/press-release/agreement-acquire-labor-dr-merk

Contact information

Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The Remittance Effect: Global Citizens Emerge as Economic First Responders of the Developing World27.1.2021 10:03:00 CETPress release

Person-to-person ("P2P") international transfers, or remittances, sent by global citizens to their homelands represent the largest foreign economic support structure for developing economies. According to a new report by Oxford Economics, commissioned by Western Union (NYSE: WU), a global leader in cross-border, cross-currency money movement, remittances have helped smooth COVID-19 pandemic-induced economic shocks, increasing the resilience of developing nations throughout 2020 and presenting a potential lifeline for recovery in 2021 and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210127005359/en/ The Remittance Effect: Global Citizens Emerge as Economic First Responders of the Developing World (Graphic: Business Wire) The Oxford Economics Report: The Remittance Effect: A Lifeline for Developing Economies Through the Pandemic and Into Recoveryidentifies several positive economic and remittance consumer fundamental

Temenos Extends Partnership with Schroders for Wealth Front Office27.1.2021 08:30:00 CETPress release

Temenos (SIX: TEMN), the banking software company, today announced that Schroders Wealth Management in Switzerland has selected Temenos Wealth Front Office to automate and enhance its advisory business. Schroders Wealth Management will deploy the state-of-the-art portfolio management system on its existing Temenos Transact core banking platform to provide intuitive and powerful capabilities for relationship managers, advisers and portfolio managers. Supported by Temenos, Schroders Wealth Management looks after £65.7 billion of assets for its clients worldwide, from offices in the UK, Channel Islands, Switzerland, Singapore and Hong Kong. With Temenos Wealth Front Office, Schroders Wealth Management benefits from standardized advisory processes. The solution includes dashboards for relationship managers and portfolio managers, client and investment profiling, investment proposal process, advanced order generation, comprehensive pre- and post-trade compliance checks, flexible benchmarkin

Data Gumbo Provides Real-Time OPEX Visibility; Supports Continuous Financial Management Across European Energy Sector27.1.2021 07:00:00 CETPress release

Data Gumbo, provider of GumboNet™ — the massively interconnected industrial smart contract network secured and powered by blockchain — today announced that it enables real-time operational expenses (OPEX) visibility for energy operators and service providers across Europe. By using field operating data to digitally confirm that commercial terms of existing contracts have been satisfied, smart contracts trigger automated payments between commercial counterparties to deliver real-time visibility into contract spend. “Energy operators and service providers are in need of information that can assist them in making difficult economic choices,” said Ove Sandve, Norway Country Manager at Data Gumbo. “GumboNet’s real-time OPEX capabilities unlock sustained digital visibility into financial health and management that can set up a company to tie field measurements to payments driving transactional certainty, improving cash flow, increasing value, and ultimately, attracting better investors.” Man

TransferWise and Visa Announce Global Partnership Following Successful Collaboration on Cloud Technology27.1.2021 06:01:00 CETPress release

Visa (NYSE: V) and TransferWise today announced a global partnership and the first use of Visa Cloud Connect, a new way for fintechs and partners to securely connect Visa’s global processing network, VisaNet, through the cloud. Visa Cloud Connect underpins a new global agreement between Visa and TransferWise that will enable the expansion of TransferWise’s multi-currency debit cards in Asia Pacific, Europe, Latin America and the Caribbean, the Middle East, U.K. and U.S. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126006164/en/ The TransferWise multi-currency account allows consumers and businesses to hold and convert 55 currencies at the real exchange rate. The multi-currency debit card lets customers spend and withdraw directly from any of the currency balances. Expanding the offering into new markets would have previously required significant investment in local data centers, telecommunications infrastructure and spe

UserTesting Launches New Test Types and Interactive Visualization Capabilities to Bring Greater Customer Insight and Intuition to Businesses27.1.2021 03:00:00 CETPress release

Collecting fast customer feedback has become mission-critical when competing in what is a very new and different business world. The ability to empathize with customers and understand how their buying behaviors have changed has never been more important than it is today. UserTesting, a leading provider of on-demand human insight, today announced several new capabilities designed to help companies meet the ever-evolving needs of their customers, with more test types that can give a greater understanding of how they organize and prioritize information, and interpret experiences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005448/en/ UserTesting January Product Release 2021 (Graphic: Business Wire) The January 2021 Product Release includes new test types for both web and mobile experiences, plus interactive visualization capabilities in the form of click maps, designed to reduce the amount of time it takes to review an

KPMG unveils Our Impact Plan ; shares progress against newly created Stakeholder Capitalism Metrics27.1.2021 01:01:00 CETPress release

KPMG today published its first global environmental, social and governance (ESG) plan. Our Impact Plan brings together new and existing ESG commitments under one umbrella, focusing on four important categories: Planet, People, Prosperity and Governance. The plan also catalogues current data across the global organization and reports against metrics outlined in a report created by the World Economic Forum (WEF) and drafted in consultation with its International Business Council (IBC), titled Measuring Stakeholder Capitalism, which KPMG had a key role in shaping. KPMG will continue to strengthen its commitments outlined in the plan and improve reporting on its progress in the months and years to come. KPMG Global Chairman and CEO, Bill Thomas said, “By harnessing our convening power, digital capabilities and expertise, KPMG has an opportunity and responsibility to help shape and lead on some of the critical issues the world faces—doing so is core to our purpose to Inspire Confidence and

PerkinElmer Launches Industry-First GPCR TR-FRET Binding Assay and Beta-Arrestin Kits to Help Advance Therapeutics Discovery26.1.2021 21:25:00 CETPress release

PerkinElmer, a global leader committed to innovating for a healthier world, today announced the addition of new assay kits to help further GPCR (G Protein-Coupled Receptor) therapeutic discovery. The new PerkinElmer offerings extend the company’s leading GPCR analysis portfolio, which includes innovative assays, plate readers, automation technologies and software solutions combined with siRNA, shRNA, CRISPR, and cDNA/ORFlibraries to help scientists more easily and accurately characterize receptors, screen compounds and streamline workflows. The new assays, which enable researchers to use the preferred cell models of their choice, include the HTRF GTP Gi binding kit, the industry’s first TR-FRET based assay for GTP binding; the B-arr2 recruitment kit; and HTRF total kits for B-Arrestin 1, B-Arrestin 2 and AP2. These assays will help scientists continue to better understand the important role GPCRs play in disease by studying the interaction, expression and potential modulation of intrac